Postmenopausal osteoporotic hip fracture
Conditions
Interventions
Group A:Administer once daily. Teriparatide (20 µg per dose, administered once daily for three consecutive months)
Group B:Administer the drug twice a week. Teriparatide (28.5 µg per dose, twice a week, for a total of three months of continuous administration)
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
Female
Age
60 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Age: 60 - 85 years (inclusive of the boundary value); 2. Fresh hip fractures after menopause confirmed by medical history and X-ray, and the time of fracture occurrence is = 20 ng/mL. If all other inclusion and exclusion criteria are met, the subjects can be given vitamin D and then re-tested; 5. PTH (15-65 pg/mL) and Ca (2.2-2.7 mmol/L) are within the normal detection range; 6. Fully capable of civil conduct, understanding the research process and methods, voluntarily participating in this trial, and signing the informed consent form in person.
Exclusion criteria
Exclusion criteria: 1. There are patients with bone metabolism disorders other than osteoporosis (such as osteomalacia, osteogenesis imperfecta, Paget's disease, Cushing's syndrome, hyperprolactinemia, etc.); 2. Before screening, they have used drugs that affect bone metabolism: within 2 years, they have used intravenous bisphosphonates, fluorides or strontium; within 6 months, they have used teriparatide or denosumab; the last oral bisphosphonate use was less than 1 year ago (excluding those with cumulative use 8.5%, severe arrhythmia); 8. Are allergic to teriparatide; 9. Are currently participating in other drug clinical trials; 10. There are other conditions that the investigator deems unsuitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum procollagen type I N-terminal propeptide (P1NP);Serum ß-type I collagen C-terminal peptide cross-linking (ß-CTX);Alkaline phosphatase (ALP); | — |
Secondary
| Measure | Time frame |
|---|---|
| Bone mineral density of lumbar spine and total hip; | — |
Countries
China
Contacts
Public ContactCao Yongping
Peking University First Hospital
Outcome results
None listed